CompletedPhase 2

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

United States22 participantsStarted 2020-08-05

Plain-language summary

The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM) * Have no evidence of metastatic disease confirmed by imaging * Be treatment naïve for IL/CM Exclusion Criteria: * Have known contraindications or sensitivities to the study drug or laser * Active ocular disease

What they're measuring

Treatment related AEs and treatment related serious adverse events (SAEs).

Timeframe: 52 weeks

Trial details

NCT IDNCT04417530

SponsorAura Biosciences

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-04-22

View on ClinicalTrials.gov More Uveal Melanoma trials